ETHERNA IMMUNOTHERAPIES
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
ETHERNA IMMUNOTHERAPIES
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2013-01-01
Address:
Jette, Brussels Hoofdstedelijk Gewest, Belgium
Country:
Belgium
Website Url:
http://www.etherna.be
Total Employee:
11+
Status:
Active
Contact:
+32 3 369 17 40
Total Funding:
111.78 M USD
Technology used in webpage:
LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Nginx Google Maps JsDelivr Cloudflare JS CDN JS ShareThis
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fund+
Fund+ investment in Series B - eTheRNA immunotherapies
Novalis LifeSciences
Novalis LifeSciences investment in Series B - eTheRNA immunotherapies
Life Sciences Partners
Life Sciences Partners investment in Series B - eTheRNA immunotherapies
Omega Funds
Omega Funds investment in Series B - eTheRNA immunotherapies
Grand Pharma
Grand Pharma investment in Series B - eTheRNA immunotherapies
Kenneth Chien
Kenneth Chien investment in Series B - eTheRNA immunotherapies
PMV
PMV investment in Series B - eTheRNA immunotherapies
European Commission
European Commission investment in Grant - eTheRNA immunotherapies
Novalis LifeSciences
Novalis LifeSciences investment in Series B - eTheRNA immunotherapies
BNP Paribas Private Equity
BNP Paribas Private Equity investment in Series B - eTheRNA immunotherapies
Official Site Inspections
http://www.etherna.be Semrush global rank: 4.87 M Semrush visits lastest month: 1.81 K
- Host name: 199.60.103.82
- IP address: 199.60.103.82
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "eTheRNA immunotherapies"
Who we are - etherna
At etherna, we have the skills and technologies to provide our partners with top-notch support in their development & manufacturing needs to acquire nucleic acid-based therapeutics and vaccines. We have an expansive portfolio of …See details»
Management team - etherna
At etherna, we have the skills and technologies to provide our partners with top-notch support in their development & manufacturing needs to acquire nucleic acid-based therapeutics and …See details»
etherna immunotherapies - Crunchbase Company …
Organization. etherna immunotherapies . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... etherna’s mission is to be a technology leader in the development of nucleic acid-based …See details»
Etherna N.V. - Life-Sciences-Europe.com
Oct 17, 2023 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry …See details»
etherna - LinkedIn
Etherna | 12,148 followers on LinkedIn. Advancing RNA Medicine. Together. | www.etherna.be | www.ethernamanufacturing.com | Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry | …See details»
eTheRNA - At.Las
ETheRNA immunotherapies is a clinical-stage Belgian biotech company applying mRNA based immunotherapies for the treatment of cancer and infectious diseases. eTheRNA was established in January 2013 as a spin-off company …See details»
etherna - wetenschapsparkuantwerpen.be
Etherna is developing world-class mRNA immunotherapies for the treatment of cancer and infectious diseases. etherna uses messenger RNA to unleash and enhance a patient's …See details»
Etherna - flanders.bio
#R&D Services - CMO (Contract Manufacturing Organization) eTheRNA BVBA is a spin-off company from VUB. The company was created in 2013 by Prof. Kris Thielemans out of the Laboratory of Molecular and Cellular Therapy (LMCT). …See details»
Our culture - etherna
At etherna, we have the skills and technologies to provide our partners with top-notch support in their development & manufacturing needs to acquire nucleic acid-based therapeutics and …See details»
Etherna | IIC UGent
Etherna is an mRNA technology platform company with fully integrated capabilities including mRNA construct design and optimization, coupled with specialized expertise in designing and …See details»
mRNA/LNP technology platform company etherna names Bernard …
Oct 17, 2023 Marijn Dekkers, new etherna Chairman said: "I am honored to be asked to take the role of Chairman at this exciting Company and working closely with Bernard, the etherna …See details»
etherna - PharmaSource
Etherna is a comprehensive supplier to the pharmaceutical industry, specialising in drug discovery services. As a Contract Manufacturing Organisation (CMO) and Contract Development and …See details»
About - etherna
Landmark peer-reviewed paper shows etherna LNP formulations for intramuscular injection combine the induction of strong immune responses with significantly reduced local …See details»
Millions in funding and new board members for mRNA company …
Aug 24, 2022 The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing. Belgium-based eTheRNA will use the money to expand investment in …See details»
eTheRNA Company Profile - Office Locations, Competitors, …
ETheRNA has 5 employees across 4 locations and $66.27 m in total funding,. See insights on eTheRNA including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Belgium's eTheRNA gets EU grant to develop mRNA cancer vaccines
Mar 22, 2021 Belgian immunotherapy firm eTheRNA has received a €6.9 million grant from the European Commission to accelerate clinical development of mRNA therapies for hard-to-treat …See details»
Press releases - etherna
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology. READ MORE > October 17, 2023 | News . mRNA/LNP technology …See details»
Etherna | Sito ufficiale
Etherna is the platform that allows simple and transparent use of Blockchain technology for any application and process integration, offering different services based on blockchain …See details»
News Archives - etherna
3 days ago Niel, Belgium, December 10, 2024. etherna, a biotech company pioneering mRNA and Lipid-based-nanoparticle (LNP) technologies, ... and the fact that the mRNA Technology …See details»